[Skip to Content]
[Skip to Content Landing]
July 18, 1980

Adjuvant Chemotherapy for Stage II and III Breast Carcinoma

Author Affiliations

From Northwestern University Medical School, Chicago (Drs Caprini, Oviedo, Khandekar, and Scanlon); Evanston Hospital, Evanston, III (Drs Caprini, Khandekar, and Scanlon); Northwestern Memorial Hospital, Chicago (Dr Oviedo); The University of Illinois, Abraham Lincoln School of Medicine, and Saint Francis Hospital, Evanston, III (Drs Cunningham and Trueheart); and Northwestern University, Vogelback Computing Center, Evanston, III (Dr Cohen).

JAMA. 1980;244(3):243-246. doi:10.1001/jama.1980.03310030019017

Stage II or III breast carcinoma patients were assigned to one of three adjuvant chemotherapy groups after mastectomy. The efficacy of melphalan, vs cyclophosphamide, fluorouracil, and prednisone (CFP), vs CFP plus BCG vaccine was compared in 173 patients treated for five days every six weeks for the first postoperative year. Tumor size, unfavorable local signs, extent of axillary nodal involvement, menopausal status, and participating hospital were considered in assigning patients to treatment groups. The median follow-up time was 26 months; 24.2% of the patients were studied for more than three years. Recurrent disease occurred in 31.6% of the patients in the melphalan group and in 13.4% and 13.2% in the other two groups. Six patients died of metastatic tumor; three others died of other causes. A favorable significant difference exists for polychemotherapy in prolonging disease-free interval in our series.

(JAMA 244:243-246, 1980)